A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

NCT04855929 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Adult Disease
Lung Cancer

Interventions

DRUG: ANV419
DRUG: Ipilimumab

Sponsor

Anaveon AG